- Home
- CELC vs NRIM Comparison
CELC vs NRIM Comparison
Compare CELC & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- NRIM
- Stock Information
- Founded
- CELC 2011
- NRIM 1990
- Country
- CELC United States
- NRIM United States
- Employees
- CELC N/A
- NRIM N/A
- Industry
- CELC Medical Specialities
- NRIM Savings Institutions
- Sector
- CELC Health Care
- NRIM Finance
- Exchange
- CELC Nasdaq
- NRIM Nasdaq
- Market Cap
- CELC 489.7M
- NRIM 474.2M
- IPO Year
- CELC 2017
- NRIM N/A
- Fundamental
- Price
- CELC $10.93
- NRIM $78.44
- Analyst Decision
- CELC Strong Buy
- NRIM
- Analyst Count
- CELC 6
- NRIM 0
- Target Price
- CELC $29.17
- NRIM N/A
- AVG Volume (30 Days)
- CELC 356.6K
- NRIM 66.2K
- Earning Date
- CELC 11-14-2024
- NRIM 01-27-2025
- Dividend Yield
- CELC N/A
- NRIM 3.14%
- EPS Growth
- CELC N/A
- NRIM 22.45
- EPS
- CELC N/A
- NRIM 5.86
- Revenue
- CELC N/A
- NRIM $141,590,000.00
- Revenue This Year
- CELC N/A
- NRIM N/A
- Revenue Next Year
- CELC N/A
- NRIM $5.97
- P/E Ratio
- CELC N/A
- NRIM $13.38
- Revenue Growth
- CELC N/A
- NRIM 12.70
- 52 Week Low
- CELC $10.35
- NRIM $43.92
- 52 Week High
- CELC $22.19
- NRIM $91.72
- Technical
- Relative Strength Index (RSI)
- CELC 35.65
- NRIM 51.22
- Support Level
- CELC $10.35
- NRIM $68.90
- Resistance Level
- CELC $13.80
- NRIM $78.80
- Average True Range (ATR)
- CELC 0.83
- NRIM 2.70
- MACD
- CELC -0.19
- NRIM 0.25
- Stochastic Oscillator
- CELC 16.20
- NRIM 85.56
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The company operates in two segments: Community Banking and Home Mortgage Lending. It generates maximum revenue from the Community Banking segment. It offers to spend and save products such as checking, savings, money market accounts, debit cards, cashback rewards, and credit cards. It also includes loans and credit lines, mortgage loans, investment, and plan products.